Thalidomide targets EGFL6 to inhibit EGFL6/PAX6 axis-driven angiogenesis in small bowel vascular malformation
Open Access
- 1 February 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cellular and Molecular Life Sciences
- Vol. 77 (24), 5207-5221
- https://doi.org/10.1007/s00018-020-03465-3
Abstract
Background Small bowel vascular malformation disease (SBVM) is the most common cause of obscure gastrointestinal bleeding (OGIB). Several studies suggested that EGFL6 was able to promote the growth of tumor endothelial cells by forming tumor vessels. To date, it remains unclear how EGFL6 promotes pathological angiogenesis in SBVM and whether EGFL6 is a target of thalidomide. Methods We took advantage of SBVM plasma and tissue samples and compared the expression of EGFL6 between SBVM patients and healthy people via ELISA and Immunohistochemistry. We elucidated the underlying function of EGFL6 in SBVM in vitro and by generating a zebrafish model that overexpresses EGFL6, The cycloheximide (CHX)-chase experiment and CoIP assays were conducted to demonstrate that thalidomide can promote the degradation of EGFL6 by targeting CRBN. Results The analysis of SBVM plasma and tissue samples revealed that EGFL6 was overexpressed in the patients compared to healthy people. Using in vitro and in vivo assays, we demonstrated that an EMT pathway triggered by the EGFL6/PAX6 axis is involved in the pathogenesis of SBVM. Furthermore, through in vitro and in vivo assays, we elucidated that thalidomide can function as anti-angiogenesis medicine through the regulation of EGFL6 in a proteasome-dependent manner. Finally, we found that CRBN can mediate the effect of thalidomide on EGFL6 expression and that the CRBN protein interacts with EGFL6 via a Lon N-terminal peptide. Conclusion Our findings revealed a key role for EGFL6 in SBVM pathogenesis and provided a mechanism explaining why thalidomide can cure small bowel bleeding resulting from SBVM.Keywords
Funding Information
- National Natural Science Foundation of China (81670505)
- the Shanghai Municipal Education Commission: Gaofeng Clinical Medicine grant support (DLY201501)
- the Three,year action plan for Shin Kang of Shanghai (16CR3113B)
- Cross medical research fund of translational medicine, Shanghai Jiao Tong Universit (ZHYXJCZDAL 190005)
This publication has 37 references indexed in Scilit:
- Analysis of Gene Expression Profiling in Meningioma: Deregulated Signaling Pathways Associated with Meningioma and EGFL6 Overexpression in Benign Meningioma Tissue and SerumPLOS ONE, 2012
- Effects of Fatty Acid Treatments on the Dexamethasone-Induced Intramuscular Lipid Accumulation in ChickensPLOS ONE, 2012
- Deciphering the mystery of thalidomide teratogenicityCongenital Anomalies, 2012
- Vascular endothelial growth factor (VEGF) isoform regulation of early forebrain developmentDevelopmental Biology, 2011
- Overexpression of Pax6 in Mouse Cornea Directly Alters Corneal Epithelial Cells: Changes in Immune Function, Vascularization, and DifferentiationInvestigative Ophthalmology & Visual Science, 2011
- EGFL6 Promotes Endothelial Cell Migration and Angiogenesis through the Activation of Extracellular Signal-regulated KinaseOnline Journal of Public Health Informatics, 2011
- Dynamics of endothelial cell behavior in sprouting angiogenesisCurrent Opinion in Cell Biology, 2010
- Tumor Vascular Proteins As Biomarkers in Ovarian CancerJournal of Clinical Oncology, 2007
- Neurogenic effect of vascular endothelial growth factor during germ layer formation of human embryonic stem cellsFEBS Letters, 2006
- Cloning of a Novel Epidermal Growth Factor Repeat Containing Gene EGFL6: Expressed in Tumor and Fetal TissuesGenomics, 1999